Onco Actu du 10 septembre 2015

	2.5 Etiologie - Gènes
Nearly half of testicular cancer risk comes from inherited genetic faults [The Institute of Cancer Research] The research suggests genetic inheritance is much more important in testicular cancer than in most other cancer types, where genetics typically accounts for less than 20% of risk.
	3.1 Tabac
No conclusive evidence that e-cigs tempt teens to smoke [NHS Choices] This study leaves many unanswered questions, such as why young people tried e-cigarettes or tobacco. Ultimately, this is a very small number to base such sweeping conclusions on.
	3.3 Prévention - Vaccins
Leaving boys out of HPV vaccination program doesn’t make sense: doctor [The Globe and Mail] Dr. Lillian Siu, senior medical oncologist at the Princess Margaret Cancer Centre and study author, said the results are compelling and should put an end to the idea the HPV vaccine is for girls only.
	4.10 Dép., diag. & prono. - Poumon
Myriad Adds to Scientific Evidence for the myPlan(R) Lung Cancer Prognostic Test [Myriad] The first study showed that the myPlan Lung Cancer test identified more patients with Stage IB lung cancer who are at risk for disease progression than were identified with National Comprehensive Cancer Network (NCCN) high-risk factors alone. The second study highlighted the successful analytical validation of the myPlan test, which demonstrated very high analytical precision.
	4.12 Biopsies liquides
Simple blood test could one day diagnose all cancers [The Telegraph] The new blood test, which researchers estimate would cost the NHS a few hundred pounds, could be a less invasive but still accurate method for a large number of patients with suspected cancer.
	5. Traitements
Chasing Cancer Stem Cells [In the Pipeline] These are fundamental questions in clinical oncology that we just don’t quite have the answers for yet. You can hope that Stemcentrx is on to something, but we’ll see how things go in the clinic – which is, as usual, where it really matters.
	5.3 Traitements - FDA, EMA,...
U.S. FDA Grants Priority Review to Takeda's Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma [Takeda] The NDA submission for ixazomib was primarily based on the results of the first pre-specified interim analysis of the pivotal Phase 3 trial, TOURMALINE-MM1.
	5.4 Traitements - Economie
Contributing Op-Ed Writer: The Solution to Drug Prices [NY Times] While the Australian system of price controls is one approach, another possibility is the Swiss health system, which is frequently applauded by conservative commentators. The Swiss government includes only those drugs that are effective and cost-effective on its approved drug list. It then establishes a maximum allowable price for the drug, but up to that point, companies can decide what to charge.
	6. Lutte contre les cancers
IASLC Wednesday Press Briefing Summary [IASLC] Dr. Gandara introduced the press conference panel that focused exclusively on the science of lung cancer research and noted that it is unlikely that there will be a single solution to defeating lung cancer. But recent research shows that investigators are refining the concept of “‘bench to bedside” and that the pace of bringing laboratory discoveries into the clinic is accelerating.
Teaming Up Against Ovarian Cancer [CANCER RESEARCH Catalyst] September is Ovarian Cancer Awareness Month, when we scientists and advocates renew our determination to find new solutions to this devastating disease. This year we are pleased to have seen some encouraging signs.
	6.1 Observation
Increased detection of low-risk tumors driving up thyroid cancer rates [Mayo Clinic] “We are spotting more cancers, but they are cancers that are not likely to cause harm,” says the study's lead author.
Breast Cancer Incidence, Death Rates Rising in Some Countries [ACS] The findings come from a new report examining global patterns and trends in breast cancer using the most up-to-date cancer registry-based data available. It appears early online in Cancer Epidemiology Biomarkers and Prevention.
	6.4 Médico-éco
CMS Payment Policy Adds Administrative Burden, Doesn’t Consider True Cost of Cancer Care [ASCO] In a comment letter to CMS on the Proposed Rule for the Medicare Physician Fee Schedule (MPFS), ASCO makes 23 specific recommendations that focus on patient care, physician payment, quality of care, and other important issues.